PALO ALTO, Calif., May 4, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., chief executive officer, is an honoree at this year's American Liver Foundation's Salute to Excellence Awards Gala to be held Thursday, May 7, 2015 at 5:30 p.m. Pacific Time, at the Palace Hotel in San Francisco.
The Northern California Division of the American Liver Foundation (ALF) is holding the event to honor industry and medical leaders whose contributions have advanced research, increased knowledge and educational outreach, and improved the quality of patient's lives. The Salute to Excellence Awards Gala has raised more than $4 million to benefit the ALF.
"I am truly honored to be among those recognized by the Foundation," said Dr. Grais. "My personal experience as a physician treating patients is my inspiration to go to work every day. Serious liver disease impacts millions of patients and their families. We at Ocera Therapeutics are committed to finding much needed alternatives to current treatments for these patients."
The Gala hosts more than 250 local notables, influential supporters, doctors, medical professionals, strategic partners and business leaders in the healthcare and biotech industries. In addition to the awards ceremony, the gala will also feature a VIP reception, cocktails and a silent auction, and a seated dinner.
For additional information about the 17th Annual Gala, or to support the event, please visit www.alfgala.org.
About the American Liver Foundation
The American Liver Foundation provides research, education, advocacy, and support for 30 million Americans affected by liver disease. The ALF's mission is to facilitate, advocate and promote education, support and research for the prevention, treatment and cure of liver disease.
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.
CONTACT: Susan Sharpe Ocera Therapeutics, Inc. firstname.lastname@example.org 919-328-1109
Source:Ocera Therapeutics, Inc.